Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore

News

Stay up to date on the latest crypto trends with our expert, in-depth coverage.

banner
Flash
07:50
Analyst: Reiterates Buy Rating on Strategy MSTR, Sets 2026 Price Target at $440
According to Odaily, Lance Vitanza, analyst at investment bank TD Cowen with $15 billion in assets, reiterated a Buy rating on Bitcoin holding company Strategy MSTR, with a target price of $440 for 2026. (BitcoinTreasuries.NET)
07:30
Synthetic fiber prices surge as Middle East conflict spreads to the textile industry
China's textile industry holds a leading position globally, and the price of synthetic fibers — a core raw material for the textile industry — is directly linked to crude oil. As chemical fiber products are inseparable from basic chemical raw materials refined from oil, every increase in crude oil prices is directly reflected in the company's production process. From the overall market perspective, prices of synthetic fibers have risen to varying degrees: for example, polyester filament yarn, a major product category of polyester, increased from about 7,180 yuan per ton in March this year to 9,300 yuan per ton; certain types of nylon have seen weekly price increases of more than 6%, and some models experienced a single-day jump of 2,000 yuan per ton. (CCTV Finance)
07:17
More than 600,000 prescriptions have been issued for oral semaglutide weight loss drug; Novo Nordisk CEO says weight loss drug market has only scratched the surface
Golden Ten Data April 6|According to the latest disclosed data from Novo Nordisk, prescriptions for its oral weight loss drug semaglutide currently exceed 600,000. UBS estimates that the combined revenue of Eli Lilly’s oral weight loss drug and Novo Nordisk’s oral version of semaglutide will reach approximately 5 billion USD in 2026. However, in the view of Novo Nordisk’s CEO, the weight loss drug market is vast, and the pharmaceutical industry has only scratched the surface. He stated that, including Novo Nordisk, Eli Lilly, and several U.S. producers of compound weight loss drugs, the current supply of weight loss medications can meet only 10% to 15% of the demand among obesity patients.
News